Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569998 | 0.83 | SLC6A3 (0.47) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL31318316 | 0.83 | SLC6A3 (0.78) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL1775832 | 0.83 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL27843639 | 0.83 | SLC6A3 (0.74) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL249 | 0.81 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL68818 | 0.81 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL8923988 | 0.81 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL2568133 | 0.81 | CYP1A2 (0.51) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| SCHEMBL6776132 | 0.81 | ALDH1A1 (0.48) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E | |
| Phosphine SCHEMBL11469830 | 0.81 | SLC6A3 (0.72) | SLC6A3SLC6A4SLC6A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327001-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2022-04-13 | — | — | EP | disclosed |
| CN-108349875-B | Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient | 东国大学校产学协力团 | 2021-08-27 | — | — | CN | disclosed |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-08-02 | — | — | US | disclosed |
| EP-3327001-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
| US-9522873-B2 | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-12-20 | — | — | US | disclosed |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | AVENTIS PHARMACEUTICALS INC. | 2003-08-14 | — | — | US | disclosed |
| US-6541505-B1 | Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin. | AVENTIS PHARMACEUTICALS INC. | 2003-04-01 | — | — | US | disclosed |
| CN-1333766-A | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors | AVENTIS PHARM PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1140901-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| US-5236937-A | Treating hypertension, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0499415-A1 | Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists | ZENECA LIMITED (GB) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | SLC6A3 2791/4885SLC6A4 3408/4885SLC6A2 1126/4885 |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | CD47, MSR1, CD14 | SLC6A3 366/4885SLC6A4 1163/4885SLC6A2 771/4885 |
| US-20180215706-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | SLC6A3 4540/4885SLC6A4 3712/4885SLC6A2 2702/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | SLC6A3 3695/4885SLC6A4 4110/4885SLC6A2 2597/4885 |
| US-20030153604-A1 | Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds | SERPINC1, F2, F11 | SLC6A3 4739/4885SLC6A4 4740/4885SLC6A2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.